| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T1 |
0-174 |
DRI_Background |
denotes |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). |
| T2 |
175-319 |
DRI_Background |
denotes |
BACKGROUND: The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) first broke out in Wuhan (China) and subsequently spread worldwide. |
| T3 |
320-392 |
DRI_Background |
denotes |
Chloroquine has been sporadically used in treating SARS-CoV-2 infection. |
| T4 |
393-573 |
DRI_Challenge |
denotes |
Hydroxychloroquine shares the same mechanism of action as chloroquine, but its more tolerable safety profile makes it the preferred drug to treat malaria and autoimmune conditions. |
| T5 |
574-763 |
DRI_Outcome |
denotes |
We propose that the immunomodulatory effect of hydroxychloroquine also may be useful in controlling the cytokine storm that occurs late-phase in critically ill SARS-CoV-2 infected patients. |
| T6 |
764-861 |
DRI_Background |
denotes |
Currently, there is no evidence to support the use of hydroxychloroquine in SARS-CoV-2 infection. |
| T7 |
862-986 |
DRI_Background |
denotes |
METHODS: The pharmacological activity of chloroquine and hydroxychloroquine was tested using SARS-CoV-2 infected Vero cells. |
| T8 |
987-1117 |
DRI_Outcome |
denotes |
Physiologically-based pharmacokinetic models (PBPK) were implemented for both drugs separately by integrating their in vitro data. |
| T9 |
1118-1321 |
DRI_Background |
denotes |
Using the PBPK models, hydroxychloroquine concentrations in lung fluid were simulated under 5 different dosing regimens to explore the most effective regimen whilst considering the drug's safety profile. |
| T10 |
1322-1434 |
DRI_Outcome |
denotes |
RESULTS: Hydroxychloroquine (EC50=0.72 μM) was found to be more potent than chloroquine (EC50=5.47 μM) in vitro. |
| T11 |
1769-1877 |
DRI_Outcome |
denotes |
CONCLUSIONS: Hydroxychloroquine was found to be more potent than chloroquine to inhibit SARS-CoV-2 in vitro. |
